Oakbrook Investments LLC boosted its position in shares of Endo International PLC (NASDAQ:ENDP) by 8.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 17,100 shares of the company’s stock after buying an additional 1,300 shares during the period. Oakbrook Investments LLC’s holdings in Endo International PLC were worth $191,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. First Quadrant L P CA bought a new stake in shares of Endo International PLC during the first quarter valued at about $24,556,000. OppenheimerFunds Inc. boosted its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Norges Bank bought a new stake in shares of Endo International PLC during the fourth quarter valued at about $26,929,000. Bank of New York Mellon Corp boosted its stake in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares in the last quarter. Hedge funds and other institutional investors own 92.27% of the company’s stock.
Shares of Endo International PLC (ENDP) opened at 8.72 on Friday. Endo International PLC has a one year low of $7.41 and a one year high of $24.93. The company’s market capitalization is $1.95 billion. The firm has a 50-day moving average of $10.47 and a 200-day moving average of $11.43.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Analysts forecast that Endo International PLC will post $3.52 earnings per share for the current year.
Several brokerages recently issued reports on ENDP. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a report on Tuesday, August 8th. Royal Bank Of Canada set a $9.00 target price on shares of Endo International PLC and gave the stock a “hold” rating in a report on Thursday, August 10th. Cowen and Company restated a “hold” rating and issued a $16.00 target price on shares of Endo International PLC in a report on Thursday, August 10th. Guggenheim began coverage on shares of Endo International PLC in a research note on Saturday, June 17th. They set a “hold” rating and a $12.00 price target on the stock. Finally, BidaskClub upgraded shares of Endo International PLC from a “strong sell” rating to a “sell” rating in a research note on Friday. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.75.
In related news, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were acquired at an average cost of $7.70 per share, with a total value of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Paul Campanelli acquired 6,500 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were bought at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the acquisition, the chief executive officer now owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 36,000 shares of company stock worth $279,460. Insiders own 0.50% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
